Clinical Trials Logo

Preeclampsia Severe clinical trials

View clinical trials related to Preeclampsia Severe.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06373367 Not yet recruiting - Preeclampsia Clinical Trials

Preeclampsia Educational Program Study (PrEPS)

PrEPS
Start date: May 1, 2024
Phase: N/A
Study type: Interventional

Preeclampsia complicates approximately 8% of all pregnancies. A critical factor of outpatient monitoring is patient education; specifically, education regarding nature of the disease, ongoing short- and long-term risks, and warning signs and symptoms for worsening of disease. This study aims to compare patient knowledge using a novel illustration based app compared to standard discharge instructions.

NCT ID: NCT05232994 Not yet recruiting - Preeclampsia Severe Clinical Trials

Metformin and Esomeprazole For Preterm Pre-eclampsia

Start date: March 1, 2023
Phase: Phase 1
Study type: Interventional

A recent randomized controlled trial by Cluver et al included 180 women with preterm pre-eclampsia between 26+0 to 31+6 weeks' gestation undergoing expectant management: 90 were randomised to extended release metformin and 90 to placebo. Investigators found that extended release metformin (3g daily) can prolong gestation in women with preterm pre-eclampsia. Combination metformin and esomeprazole has shown promise in the treatment of preeclampsia as both agents reduce placental and endothelial secretion of soluble fms-like tyrosine kinase 1 (sFlt-1) and soluble endoglin, and reduce endothelial dysfunction.

NCT ID: NCT04855513 Not yet recruiting - Preeclampsia Clinical Trials

Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial

PREMET
Start date: March 24, 2022
Phase: N/A
Study type: Interventional

This is an open label, randomized control trial (RCT) in which high risk for pre-eclampsia pregnant subjects will be randomly assigned to either an intervention group (metformin 1 gm twice daily plus aspirin 100 mg per day and standard of care) versus control group (aspirin 100 mg per day and standard of care) that will be administered between 11 to 13 weeks of gestation until delivery . Only women at high risk of pre-eclampsia as defined by the ACOG practice bulletin will be included (see inclusion criteria). Patient assignment will not be blinded as control group will not be given a placebo; the data will be analyzed on an intention to treat basis. Enrolled subjects will be followed throughout pregnancy and up to 30 days post-delivery (as per hospital practice).

NCT ID: NCT03318211 Not yet recruiting - Preeclampsia Severe Clinical Trials

Discontinuation of Magnesium Sulfate After Delivery in Women With Severe Preeclampsia. A Randomized Controlled Trial

Start date: October 25, 2017
Phase: Phase 4
Study type: Interventional

All women with severe preeclmapsia were given a loading dose of 4 g magnesium sulfate IV followed by the maintenance dose of 1 g/h infusion till the delivery. After delivery, women who received magnesium sulfate for 8 hours or more were randomly divided into two groups: Group I ( 50 cases) No magnesium sulfate received postpartum and Group II ( 50 cases)—magnesium sulfate infusion is given for conventional 24 h postpartum at a rate of 1 gm per hour